Geode Capital Management LLC Raises Holdings in Delcath Systems, Inc. (NASDAQ:DCTH)

Geode Capital Management LLC raised its stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 14.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 288,951 shares of the company's stock after buying an additional 37,056 shares during the quarter. Geode Capital Management LLC owned about 0.90% of Delcath Systems worth $3,481,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Quantbot Technologies LP bought a new position in Delcath Systems during the fourth quarter valued at approximately $66,000. Barclays PLC bought a new position in shares of Delcath Systems during the 3rd quarter valued at approximately $104,000. Jane Street Group LLC purchased a new position in shares of Delcath Systems in the third quarter valued at $110,000. Private Advisor Group LLC purchased a new position in shares of Delcath Systems in the fourth quarter valued at $153,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Delcath Systems in the 4th quarter worth about $156,000. Institutional investors own 61.12% of the company's stock.

Delcath Systems Price Performance

Shares of NASDAQ:DCTH traded up $0.18 during trading on Friday, reaching $12.26. 58,734 shares of the company were exchanged, compared to its average volume of 355,366. The business's fifty day simple moving average is $12.45 and its 200-day simple moving average is $12.47. The firm has a market capitalization of $409.82 million, a PE ratio of -9.10 and a beta of 0.85. Delcath Systems, Inc. has a 12-month low of $5.30 and a 12-month high of $16.97.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The business had revenue of $15.10 million during the quarter, compared to analysts' expectations of $14.96 million. During the same period in the previous year, the company posted ($0.48) EPS. On average, sell-side analysts anticipate that Delcath Systems, Inc. will post -0.79 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on DCTH. Craig Hallum increased their price target on Delcath Systems from $18.00 to $21.00 and gave the company a "buy" rating in a report on Friday, January 17th. HC Wainwright boosted their price objective on Delcath Systems from $22.00 to $24.00 and gave the company a "buy" rating in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Delcath Systems currently has a consensus rating of "Moderate Buy" and a consensus price target of $22.75.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.